CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

NCT07268794 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer
Prostate Cancer (Adenocarcinoma)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: Androgen Deprivation Therapy (ADT)
DRUG: Docetaxel
DRUG: PARP Inhibitors and Other Systemic Agents
PROCEDURE: Radical Prostatectomy
RADIATION: Prostate Radiotherapy

Sponsor

Fudan University